Bristol Myers Rises on Strong Eliquis and Newer Drug Sales

By EC Assets · Published 30 July 2026

Bristol Myers has revised its 2026 forecast upwards. This adjustment follows strong results, driven by the drug Eliquis and newer medications in its portfolio. The company's updated outlook reflects the performance of these key products. Eliquis, an anticoagulant, continues to be a significant contributor to the company's financial performance. Newer medicines have also played a role in strengthening the company's revenue streams. These factors combined enabled Bristol Myers to increase its financial projections for the upcoming year. This article is intended for informational purposes only. It does not constitute investment advice.